{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:18:06Z","timestamp":1791980286019,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.leukres.2025.108089","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T14:31:31Z","timestamp":1757082691000},"page":"108089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9919-3564","authenticated-orcid":false,"given":"Ehab L.","family":"Atallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam","family":"Sadek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Latremouille-Viau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Damon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Bellefleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8556-0012","authenticated-orcid":false,"given":"Kejal","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2025.108089_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer J. Clinic."},{"issue":"11","key":"10.1016\/j.leukres.2025.108089_bib2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2025.108089_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev."},{"issue":"5","key":"10.1016\/j.leukres.2025.108089_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11899-023-00703-w","article-title":"Real-world management of CML: outcomes and treatment patterns","volume":"18","author":"Held","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"2","key":"10.1016\/j.leukres.2025.108089_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.36469\/jheor.2022.36975","article-title":"Chronic myeloid leukemia: part I-real-world treatment patterns, healthcare resource utilization, and associated costs in later lines of therapy in the United States","volume":"9","author":"Atallah","year":"2022","journal-title":"J. Health Econ. Outcomes Res"},{"issue":"2","key":"10.1016\/j.leukres.2025.108089_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.36469\/jheor.2022.36976","article-title":"Chronic myeloid leukemia: part II-cost of care among patients in advanced phases or later lines of therapy in chronic phase in the United States from a commercial perspective","volume":"9","author":"Atallah","year":"2022","journal-title":"J. Health Econ. Outcomes Res"},{"issue":"2","key":"10.1016\/j.leukres.2025.108089_bib7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1185\/03007995.2015.1120189","article-title":"Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia","volume":"32","author":"McGarry","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.leukres.2025.108089_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-line therapy for chronic myeloid leukemia: current status and future directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2025.108089_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2025.108089_bib10","unstructured":"FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia\u3009."},{"issue":"21","key":"10.1016\/j.leukres.2025.108089_bib11","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2025.108089_bib12","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2025.108089_bib13","unstructured":"FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemia. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-asciminib-newly-diagnosed-chronic-myeloid-leukemia\u3009."},{"issue":"10","key":"10.1016\/j.leukres.2025.108089_bib14","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2025.108089_bib15","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myeloid Leukemia Version 3.2025.\u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 28, 2025. To view the most recent and complete version of the guideline, go online to, NCCN.org."},{"issue":"38","key":"10.1016\/j.leukres.2025.108089_bib16","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1080\/14796694.2024.2402680","article-title":"Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE phase II trial","volume":"20","author":"Atallah","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.leukres.2025.108089_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2024-200717","article-title":"Efficacy and safety of asciminib in chronic myeloid leukemia in chronic phase (CML-CP): interim results from the phase 2 ASC2ESCALATE trial in the cohort of patients (Pts) after 1 prior tyrosine kinase inhibitor (TKI)","volume":"144","author":"Atallah","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.108089_bib18","article-title":"Efficacy and safety of asciminib in chronic myeloid leukemia in chronic phase (CML-CP): interim results from the phase 2 ASC2ESCALATE trial in the cohort of patients (Pts) after 1 prior tyrosine kinase inhibitor (TKI)","author":"Atallah","year":"2024","journal-title":"Presente 66th ASH Annu. Meet. Expo."},{"issue":"3","key":"10.1016\/j.leukres.2025.108089_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2025.108089_bib20","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","article-title":"Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study","volume":"103","author":"Gambacorti-Passerini","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.leukres.2025.108089_bib21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2025.108089_bib22","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2025.108089_bib23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clml.2024.09.013","article-title":"Real-world evaluation of treatment patterns and clinical outcomes among patients with chronic myeloid leukemia in chronic phase treated with asciminib in clinical practice in the United States: real-world asciminib treatment outcomes in CML-CP","volume":"23","author":"Atallah","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"2","key":"10.1016\/j.leukres.2025.108089_bib24","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/ejh.14330","article-title":"Asciminib in advanced-line treatment of chronic myeloid leukemia","volume":"114","author":"Shacham-Abulafia","year":"2025","journal-title":"Eur. J. Haematol."},{"issue":"7","key":"10.1016\/j.leukres.2025.108089_bib25","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/imj.16446","article-title":"Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a managed access programme (MAP) in Australia","volume":"54","author":"Chee","year":"2024","journal-title":"Intern Med J."},{"key":"10.1016\/j.leukres.2025.108089_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12185-024-03873-2","article-title":"Real-world toxicity and efficacy of asciminib in heavily pretreated patients with chronic myeloid leukemia","volume":"121","author":"Ishii","year":"2025","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2025.108089_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107374","article-title":"Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy","volume":"133","author":"Khadadah","year":"2023","journal-title":"Leuk. Res"},{"issue":"1","key":"10.1016\/j.leukres.2025.108089_bib28","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3324\/haematol.2022.281386","article-title":"Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population","volume":"108","author":"Kockerols","year":"2023","journal-title":"Haematologica"},{"issue":"S3","key":"10.1016\/j.leukres.2025.108089_bib29","doi-asserted-by":"crossref","first-page":"e55133e1","DOI":"10.1097\/01.HS9.0000969648.55133.e1","article-title":"Real-world efficacy profile of asciminib in an Italian, multi-resistant chronic-phase chronic myeloid leukemia (CP-CML) patient population","volume":"7","author":"Breccia","year":"2023","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2025.108089_bib30","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1182\/blood-2022-165501","article-title":"Real-World experience of asciminib: factors associated with response","volume":"140","author":"Innes","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2025.108089_bib31","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00277-022-04932-6","article-title":"Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia","volume":"101","author":"Luna","year":"2022","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2025.108089_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41408-021-00420-8","article-title":"Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice","volume":"11","author":"Garcia-Guti\u00e9rrez","year":"2021","journal-title":"Blood Cancer J."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262500579X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262500579X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:50:46Z","timestamp":1772837446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262500579X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":32,"alternative-id":["S014521262500579X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108089","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108089"}}